Enhancing the Breadth and Efficacy of Therapeutic Vaccines for Breast Cancer
Abstract
Over the first 6 months of this award, we have focused on building a strong team, clinical collaborations, patient enrollment and samples acquisition. Our team has tested and optimized a number of protocols to process samples, generate antigen- presenting cells, and expand T cells for testing against tumor lysates from the Spellman group. This process is nearly complete, and we are positioned to work through the entire process as outlined in the SOW. We anticipate tumor-reactive T cell clones from patients will be generated starting in Year 2, which will lead downstream to antigen discovery.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2012
- Accession Number
- ADA569353
Entities
People
- Peter P Lee